1. Home
  2. WHLR vs SILO Comparison

WHLR vs SILO Comparison

Compare WHLR & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wheeler Real Estate Investment Trust Inc.

WHLR

Wheeler Real Estate Investment Trust Inc.

HOLD

Current Price

$1.80

Market Cap

1.5M

Sector

Real Estate

ML Signal

HOLD

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.50

Market Cap

7.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHLR
SILO
Founded
2011
2010
Country
United States
United States
Employees
49
N/A
Industry
Real Estate Investment Trusts
Apparel
Sector
Real Estate
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.5M
7.2M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
WHLR
SILO
Price
$1.80
$0.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
240.6K
4.6M
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.98
EPS
N/A
N/A
Revenue
N/A
$72,102.00
Revenue This Year
N/A
$1.86
Revenue Next Year
N/A
N/A
P/E Ratio
$0.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$0.22
52 Week High
$10.05
$1.13

Technical Indicators

Market Signals
Indicator
WHLR
SILO
Relative Strength Index (RSI) 59.50 54.83
Support Level $1.50 $0.29
Resistance Level $2.25 $0.68
Average True Range (ATR) 0.21 0.08
MACD 0.16 0.01
Stochastic Oscillator 54.20 38.03

Price Performance

Historical Comparison
WHLR
SILO

About WHLR Wheeler Real Estate Investment Trust Inc.

Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Cypress Shopping Center in Boiling Springs, South Carolina, and others.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Share on Social Networks: